TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00365365
Drug: Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* doxorubicin 50 mg/m\^2 IV push or infusion followed by cyclophosphamide 500 mg/m\^2 IV push or infusion followed by docetaxel 75 mg/m\^2~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy
Study: NCT00365365
Drug: Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* docetaxel in 75 mg/m\^2 IV followed by carboplatin AUC 6 mg/mL/min IV followed by~* trastuzumab 6 mg/kg by IV infusion (For the first cycle 1 only a loading dose of trastuzumab 8 mg/kg IV was infused on Day 2)~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy
Study: NCT00365365
Drug: Bevacizumab and trastuzumab maintenance therapy
Normalized name: Bevacizumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * bevacizumab 15 mg/kg was infused IV followed by~* trastuzumab 6 mg/kg IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed.
Study: NCT01234272
Drug: morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ITM-IVPCA: intrathecal administration of 0.3 mg morphine before induction of general anesthesia and application of IVPCA (basal infusion: fentanyl 0.4mcg/kg/hr, bolus: 0.16mcg/kg of fentanyl with a lock out time of 15 min)
Study: NCT01234272
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCEA: epidural administration of 5ml 0.2% ropivacaine before induction of general anesthesia and application of PCEA (basal infusion: 5ml 0.2% ropivacaine with fentanyl 0.4 mcg/kg/hr, bolus: 2ml 0.2% ropivacaine with fentanyl 0.16mcg/kg with a lockout time 15min)
Study: NCT00700271
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg or 10 mg tablets.
Study: NCT00700271
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 160 mg capsules.
Study: NCT00865072
Drug: Metformin HCl 750 mg Extender Release tablets, single dose
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions
Study: NCT00365365
Drug: Bevacizumab maintenance therapy
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: - bevacizumab 15 mg/kg was infused IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed.
Study: NCT00754325
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 100 mg, once daily (QD), upto 2 years
Study: NCT00754325
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1. In subsequent cycles, 500 mg IM administered on Day 1. IM day 1 and 15 first cycle then IM Day 1 for all other cycles for 2 years
Study: NCT00716755
Drug: Risperidone/Olanzapine and PET scans
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current risperidone/olanzapine users who are 50 or older will be recruited. Dopamine D2 dopamine receptors using a selective D2 dopamine receptor ligand, \[11C\]-raclopride, and plasma levels of risperidone and 9-OH-risperidone, or of olanzapine, and prolactin will be measured on the 1st PET visit. Subsequently, there will be gradual dose reductions of risperidone or olanzapine by 0.5 and 2.5 mg per week, respectively (as long as the total reduction does not exceed 40%). At least 5 days after the termination of the dose taper, participants will have the second PET scan. Participants will be followed up for 24 weeks after the termination of the dose reduction.
Study: NCT01634555
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 180 milligrams per square meter (mg/m²) administered IV on Day 1 of each cycle
Study: NCT01634555
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m² administered IV on Day 1 of each cycle
Study: NCT01634555
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m² bolus over 2 to 4 minutes administered IV on Day 1 of each cycle, followed by 2400 mg/m² administered IV over 46 to 48 hours on Days 1 and 2 of each cycle
Study: NCT01380431
Drug: Lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, 40 mg, single oral dose
Study: NCT01380431
Drug: lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, 40 mg, single, oral dose
Study: NCT01380431
Drug: Lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50% of subjects received the Par formulated product.
Study: NCT00643643
Drug: Maraviroc (UK-427,857)
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg oral tablet once daily for 10 days
Study: NCT00643643
Drug: Maraviroc (UK-427,857)
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg oral tablet twice daily for 10 days
Study: NCT00643643
Drug: Maraviroc (UK-427,857)
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg oral tablet twice daily for 10 days
Study: NCT00643643
Drug: Maraviroc (UK-427,857)
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg oral tablet twice daily for 10 days
Study: NCT04736186
Drug: Loperamide
Normalized name: Loperamide
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)
Study: NCT04736186
Drug: Loperamide and golden bifid
Normalized name: Golden Eye
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with secondary prevention will be randomly assigned to B：Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+golden bifid 2 g t.i.d.
Study: NCT04736186
Drug: Loperamide and montmorillonite powder
Normalized name: Montmorillonite
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with secondary prevention will be randomly assigned to D：Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+montmorillonite powder 3 g t.i.d.
Study: NCT02201407
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a treatment according to standard of care, current summary of product characteristics and in line with the local labeling.
Study: NCT01344876
Drug: OPB-51602
Normalized name: OPB-111077
DrugBank: OPB-111077 (DB16630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily during the treatment period
Study: NCT04994119
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Warfarin (Coumadin) 5 mg film coated tablets
Study: NCT01928381
Drug: AZD5213 + pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Double blind Investigational drug AZD5213 (capsules) given in combination with pregabalin (capsules)
Study: NCT01928381
Drug: pregabalin capsules
Normalized name: Pregabalin Capsules
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Double blind pregabalin capsules to match AZD5213 and placebo
Study: NCT00840866
Drug: cefprozil
Normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg Tablet
Study: NCT04197115
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
Study: NCT00002827
Drug: dexrazoxane hydrochloride
Normalized name: Dexrazoxane Hydrochloride
DrugBank: Dexrazoxane (DB00380)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00002827
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00002827
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00128544
Drug: telbivudine
Normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00128544
Drug: valtorcitabine
Normalized name: Valtorcitabine
DrugBank: Valtorcitabine (DB06187)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02135887
Drug: MB-6
Normalized name: MBS
DrugBank: Morpholinylmercaptobenzothiazole (DB14202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6# TID with meal
Study: NCT00781339
Drug: sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate
Normalized name: 2-bromo-2-methylpropane
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1% NVC-422 in saline, up to 100 mL, Study Part 1 - once on Day 1 held in the bladder for 1 hour; Study Part 2 (Part 2a - 0.1% NVC-422, Part 2b - 0.2% NVC-422), once daily for 7 days, held in the bladder for 1 hour
Study: NCT03804749
Drug: suramin sodium
Normalized name: Suramin sodium
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The trial will start from the low dose (10mg/kg) group, followed by the middle dose (15mg/kg) and high dose (20mg/kg) groups, only after the safety in the previous dose group has been demonstrated.。
Study: NCT00653003
Drug: Leflunomide
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets, 20mg, single-dose
Study: NCT00653003
Drug: ARAVA
Normalized name: Arava
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, 20mg, single-dose
Study: NCT00573443
Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 20 mg/ Q 10 mg, taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
Study: NCT00573443
Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg
Normalized name: dextromethorphan hydrobromide / quinidine sulfate Pill
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 30 mg/ Q 10 mg taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
Study: NCT00905606
Drug: Topiramate Tablets
Normalized name: Topiramate Tablets
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03039426
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% bupivacaine 20ml divided in two; 10 ml intraperitoneal infiltration and 10 ml subcutaneous infiltration
Study: NCT00562588
Drug: Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg)
Normalized name: aspirin 25 MG / dipyridamole 200 MG [Aggrenox]
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00562588
Drug: ASA 100 mg qd
Normalized name: aspirin 100 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01770132
Drug: porfimer sodium
Normalized name: Porfimer Sodium
DrugBank: Porfimer sodium (DB00707)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01770132
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01564862
Drug: vortioxetine (Lu AA21004)
Normalized name: Vortioxétine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lu AA21004 capsules
Study: NCT01564862
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duloxetine capsules
Study: NCT03809611
Drug: UNR844-Cl
Normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% Ophthalmic solution for topical ocular administration
Study: NCT00400595
Drug: Mupirocin ointment
Normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical ointment (already in widespread clinical use)
Study: NCT00400595
Drug: Polysporin Triple
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01262690
Drug: PF-05230901
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending doses of PF-05230901 in separate cohorts of subjects; each cohort consists of 6 subjects treated with PF-05230901 and 3 subjects treated with placebo.
Study: NCT01262690
Drug: PF-05230901
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose SC
Study: NCT01889004
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Escalating concentrations until loss of responsiveness
Study: NCT01889004
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escalating concentrations until loss of responsiveness
Study: NCT02193074
Drug: nusinersen
Normalized name: Nusinersen
DrugBank: Nusinersen (DB13161)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered by intrathecal (IT) injection as specified in the treatment arm.
Study: NCT02997761
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00004897
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02287857
Drug: Domestic Tenofovir Disoproxil Fumarate Tablets
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 Domestic Tenofovir Disoproxil Fumarate Tablets and 1 blank Tenofovir Disoproxil Fumarate Tablets of Gilead
Study: NCT02287857
Drug: Tenofovir Disoproxil Fumarate Tablets of Gilead
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 blank Domestic Tenofovir Disoproxil Fumarate Tablets and 1Tenofovir Disoproxil Fumarate Tablets of Gilead
Study: NCT04154735
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A chemotherapy medication commonly used in the treatment of leukemia and lymphoma
Study: NCT04154735
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
Study: NCT04154735
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A protein that kills the immune cells that are thought to be causing Crohn's; it is commonly used in the treatment of leukemia and lymphoma
Study: NCT04154735
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
Study: NCT01020864
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 500 mg/m² i.v. day 1, every 2nd week
Study: NCT01020864
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC = 3 i.v. day 1, every 21nd week
Study: NCT01020864
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine 25 mg/m² i.v. day 1, every 2nd week
Study: NCT00004897
Drug: hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04154735
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An antibiotic used to treat irritable bowel syndrome and relapsing C. difficile infection; it inhibits DNA-dependent RNA polymerase
Study: NCT04154735
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A medication which suppresses the immune system and inhibits T-lymphocytes; commonly used to lower the risk of organ rejection following transplant
Study: NCT04766307
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin 2 (IL-2) is a pleiotropic cytokine that is produced after antigen activation and plays crucial roles in the immune response. IL-2 secreted by activated T cells is central to the development of an immune response to infection, promoting the differentiation and proliferation of lymphoid cells. This hydrophobic molecule and the various cytokines that it elicits regulates the behavior of T and B lymphocytes, monocytes/macrophages, natural killer (NK) cells, and neutrophils. IL-2 therapy regimens are expected to limit mycobacterial replication. Early clinical trials with IL-2 demonstrated that IL-2 immunotherapy may be useful in controlling infectious disease.
Study: NCT02331823
Drug: Isoniazid Aminosalicylate Tablets
Normalized name: aminosalicylate
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a regimen consists of 5 anti-TB drugs (Isoniazid Aminosalicylate Tablets+pyrazinamide tablets+ethambutol tablets+rifabutin capsules+moxifloxacin tablets)to treat retreatment pulmonary tuberculosis patients. The total treatment course is 5 months.
Study: NCT04173585
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib is a small molecule dipeptide binding the catalytic site of the 26 S proteasome. It acts as a potent, reversible, and specific inhibitor of proteasomes and thus impairs the degradation of ubiquitinated proteins. It has demonstrated anti-neoplastic activity in myeloma and lymphoma. It is approved and widely used in multiple myeloma both for first line treatment and relapsed patients.
Study: NCT01808534
Drug: palifosfamide
Normalized name: Palifosfamide
DrugBank: Palifosfamide (DB05668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03887780
Drug: Rivaroxaban (Xarelto,Bay 59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg and 20 mg (OD)
Study: NCT04205604
Drug: 18F-Fluoro Dopa Imaging
Normalized name: 16alpha-(18F)Fluoro-17beta-estradiol
DrugBank: Fluoroestradiol F-18 (DB15690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaging with 18F-Fluoro Dopa PET Imaging
Study: NCT04173585
Drug: Gemtuzumab Ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab Ozogamicin is a monoclonal antibody directed against the myeloid surface antigen CD33. The antibody is linked to calicheamicin which serves as cytotoxic agent. For years, gemtuzumab ozogamicin has been tested in clinical AML trials. Though withdrawn from the US market in 2010, FDA approval was granted in September 2018, EU approval in April 2018 based on encouraging results from recent clinical trials using enhanced dosing schedules.
Study: NCT02265874
Drug: Habitrol
Normalized name: Habitrol
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patch used daily for 28 weeks
Study: NCT00276172
Drug: Natalizumab
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Natalizumab 300 mg by IV infusion, every 4 weeks, for up to 24 months
Study: NCT00938314
Drug: human chorionic gonadotropin (hCG), then epoetin alfa (EPO)
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation
Study: NCT00938314
Drug: human chorionic gonadotropin (hCG), then epoetin alfa (EPO)
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation
Study: NCT01764672
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dose 40mg (2 x 20mg)
Study: NCT02400788
Drug: Resminostat
Normalized name: resminostat
DrugBank: Resminostat (DB12392)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02400788
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04789135
Drug: Ozone
Normalized name: OZONE
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment consists of direct instillation into the bladder of ozone gas, with concentration of 20µg / ml - 60ml via urethral catheter.
Study: NCT03797625
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60mg/m2，D1，8
Study: NCT03797625
Drug: DDP
Normalized name: DDP
DrugBank: Mitometh (DB12117)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60mg/m2，D1
Study: NCT03797625
Drug: Endostar
Normalized name: Endostar
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg/d，d1-d7 civ
Study: NCT01394939
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 180 mg/m2 IV every 2 weeks.